Antineoplastic agents 365. Dolastatin 10 SAR probes

Area of Science:

• Marine natural products chemistry
• Medicinal chemistry
• Cancer pharmacology

Background:

• Dolastatin 10, a potent anticancer agent derived from Dolabella auricularia, is in clinical trials.
• Structural modifications are explored to enhance efficacy and understand structure-activity relationships.

Purpose of the Study:

• To synthesize and evaluate novel structural modifications of dolastatin 10.
• To assess the antineoplastic activity of these analogs against various cancer cell lines.
• To investigate their effects on tubulin polymerization and related binding interactions.

Main Methods:

• Synthesis of 38 new dolastatin 10 analogs.
• In vitro evaluation against human and murine cancer cell lines.
• Assays for tubulin polymerization inhibition and binding studies (vinblastine, GTP).

Main Results:

• Several new dolastatin 10 analogs demonstrated significant antineoplastic potency, some comparable to the parent compound.
• Specific modifications, particularly replacing the Doe unit with Met, Phe, or substituted phenylethylamides, yielded potent analogs.
• Antifungal and antibacterial activities were observed for one and another analog, respectively.

Conclusions:

• Structural modifications of dolastatin 10 can yield compounds with potent anticancer activity.
• The Doe unit replacement is a promising strategy for developing new antineoplastic agents.
• Some analogs may possess broader biological activities, including antimicrobial effects.